The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
A Model of Placebo Response in Antidepressant Clinical Trials
Open accessAbstract
Placebo response in clinical trials of antidepressant medications is substantial and has been increasing. High placebo response rates hamper efforts to detect signals of efficacy for new antidepressant medications, contributing to trial failures and delaying the delivery of new treatments to market. Media reports seize upon increasing placebo response and modest advantages for active drugs as reasons to question the value of antidepressant medication, which may further stigmatize treatments for depression and dissuade patients from accessing mental health care. Conversely, enhancing the factors responsible for placebo response may represent a strategy for improving available treatments for major depressive disorder. A conceptual framework describing the causes of placebo response is needed in order to develop strategies for minimizing placebo response in clinical trials, maximizing placebo response in clinical practice, and talking with depressed patients about the risks and benefits of antidepressant medications. In this review, the authors examine contributors to placebo response in antidepressant clinical trials and propose an explanatory model. Research aimed at reducing placebo response should focus on limiting patient expectancy and the intensity of therapeutic contact in antidepressant clinical trials, while the optimal strategy in clinical practice may be to combine active medication with a presentation and level of therapeutic contact designed to enhance treatment response.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are several potential explanations, as many factors have been associated with higher placebo response rates, such as randomisation ratio and the expectation of receiving an active treatment, the therapeutic setting, or the frequency of study visits.24”
In the citing paper
“Late-life depression (LLD) is a common and debilitating condition, with less frequent remission and more frequent recurrence following first-line antidepressant treatment compared to depression experienced earlier in life1–7.”
From Psychobiological factors of resilience and depression in late life (2019) · cites this paper as [5]
In the citing paper
“Whilst previous meta-analyses have demonstrated that control group responses (CGRs) can negatively influence antidepressant efficacy”
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Measurement and Control of Response Bias
Paulhus, D. L. (1991) · Measures of Personality and Social Psychological Attitudes · doi:10.1016/b978-0-12-590241-0.50006-x · Cited by 3,598
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Regression to the mean: what it is and how to deal with it
Barnett, A. G. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh299 · Cited by 1,988 · cited 1×
“One source of apparent symptom change in antidepressant trials is regression to the mean, which is a statistical phenomenon occurring when repeated measurements associated with random error are made on the same subject over time (32).”
BackgroundPlacebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 1×
“In antidepressant trials for adults, placebo response averages 31% compared to a mean medication response of 50%, and it has risen at a rate of 7% per decade over the past 30 years (1).”
BackgroundThe Functional Neuroanatomy of the Placebo Effect
Mayberg, H. S., Silva, J. A., Brannan, S. K., Tekell, J. L., Mahurin, R. K., McGinnis, S., & Jerabek, P. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.728 · Cited by 720
The Placebo Effect: Dissolving the Expectancy Versus Conditioning Debate.
Stewart-Williams, S., & Podd, J. (2004) · Psychological Bulletin · doi:10.1037/0033-2909.130.2.324 · Cited by 664
Lespérance, F., Frasure-Smith, N., Koszycki, D., Laliberté, M.-A., van Zyl, L. T., Baker, B., Swenson, J. R., Ghatavi, K., Abramson, B. L., Dorian, P., et al. (2007) · JAMA · doi:10.1001/jama.297.4.367 · Cited by 658
Newcome, F. (1968) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.31.4.409-c · Cited by 629
Research works printed but not linked: 8
- Hooper M, Amsterdam JD: Do clinical trials reflect drug potential? A review of FDA evaluation of new antidepressants, in 39th Annual Meeting Abstracts of Poster Presentations, New Clinical Drug Evaluation Unit Program, 1999
- World Health Organization, 2004, The World Health Report 2004: Changing History, Annex Table 3: Burden of Disease in DALYs by Cause, Sex, and Mortality Stratum in WHO Regions, Estimates for 2002
- Bass MJ, 1986, J Fam Pract, 23, 43
- Stettin GD, 2006, Am J Manag Care, 12, 453
- 10.1037/0022-006X.60.5.664 · DOI · Paper page
- 10.1001/jama.1984.03350060032024 · DOI · Paper page
- Liberman RP, 1967, Neuropsychopharmacology, 5, 557
- Doongaji DR, 1978, J Postgrad Med, 24, 147
Cited by
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Ionescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa068 · Cited by 418
“There is a well-known and substantial placebo response in antidepressant clinical trials due in large part to patient expectations and the intensity of therapeutic contacts (Rutherford and Roose, 2013; Leuchter et al., 2014).”
BackgroundCipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · Focus · doi:10.1176/appi.focus.16407 · Cited by 328
Motter, J. N., Pimontel, M. A., Rindskopf, D., Devanand, D. P., Doraiswamy, P. M., & Sneed, J. R. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.09.022 · Cited by 303
Blinding and expectancy confounds in psychedelic randomized controlled trials
Muthukumaraswamy, S. D., Forsyth, A., & Lumley, T. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933434 · Cited by 324
Metadata
- Authors
- Rutherford, B. R., & Roose, S. P.
- Affiliations
- New York State Psychiatric Institute (US)
- ORCID
- Rutherford, Bret R.
- Venue
- American Journal of Psychiatry
- Published
- 2013-07
- Volume
- 170
- Issue
- 7
- Pages
- 723-733
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC3628961
- OpenAlex
- W2147111327
- Cited by
- 268
- References
- 63
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 16 · 2023: 15 · 2022: 18 · 2021: 23 · 2020: 18 · 2019: 27 · 2018: 23 · 2017: 26 · 2016: 10 · 2015: 28 · 2014: 30 · 2013: 4
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (K23MH085236, T32MH015144)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- placebo response, antidepressants, major depressive disorder, clinical trial design, therapeutic contact, depression treatment, antidepressant efficacy
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Humans, Models, Psychological, Placebo Effect, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Model of Placebo Response in Antidepressant Clinical Trials. https://app.cochat.ai/papers/10.1176/appi.ajp.2012.12040474
- The paper
- Rutherford, B. R., & Roose, S. P. (2013). A Model of Placebo Response in Antidepressant Clinical Trials. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2012.12040474
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.